CTOs on the Move

Neuralstem

www.neuralstem.com

 
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.neuralstem.com
  • 20271 Goldenrod Lane 2nd Floor
    Germantown, MD USA 20876
  • Phone: 301.366.4960

Executives

Name Title Contact Details

Similar Companies

Persante Health Care

Persante Health Care is a national provider of sleep and balance center management services to hospitals, physician practices and patients. Persante`s expertise in sleep and balance related disorders dates back almost 20 years under the names of Sleep Care Centers, Sleep Tech, Mid-Atlantic School of Sleep Medicine and Blackwood Medical. The merging of these four unique industry leaders revolutionized the out-sourced delivery model of sleep and balance diagnosis and therapeutic treatment. This comprehensive approach to serving our client`s patients in a high quality manner has earned recognition and accreditation from The American Academy of Sleep Medicine and The National Sleep Foundation.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Hologram Sciences

Reimagining the future of nutrition

Radeas

Radeas is a clinical laboratory that offers testing for toxicology, COVID-19, PGX, UTI, and blood. They provide timely and accurate information to help guide decisions and ensure improved outcomes, with excellent customer service and a broad network of...

RxAlly

RxAlly was developed to provide a new solution to the critical issues of providing additional access to care and ensuring effective health care spending at a time when prescription medicine misuse is associated with $290 billion in annual costs. The RxAlly network of pharmacies aims to improve patient health through enhanced pharmacist care that combines clinical research, evidence-based clinical services and an interoperable technology platform.